A O
with O
a O
history O
of O
a O
palpable O
in O
the O
, O
which O
was O
found O
incidentally O
after O
. O

 O
The O
patient O
had O
. O

 O
On O
, O
the O
was O
found O
to O
be O
a O
nonmovable O
, O
firm O
with O
no O
or O
associated O
, O
detected O
at O
the O
( O
at O
the O
) O
. O

 O
There O
was O
no O
visible O
or O
from O
the O
. O

 O
On O
, O
we O
detected O
a O
well O
- O
circumscribed O
, O
oval O
, O
anechoic O
, O
with O
, O
that O
measured O
about O
, O
and O
was O
located O
in O
the O
over O
the O
. O

 O
In O
the O
dependent O
portion O
of O
the O
mass O
was O
an O
internal O
, O
well O
- O
circumscribed O
, O
heterogeneously O
hypoechoic O
, O
egg O
- O
shaped O
( O
Fig.1A O
and O
B O
) O
showing O
a O
. O

 O
The O
mass O
could O
be O
compressed O
using O
the O
( O
Fig.2A O
and O
B O
) O
. O

 O
A O
color O
showed O
no O
within O
the O
cystic O
mass O
or O
the O
internal O
hypoechoic O
lesion O
( O
Fig.1C O
) O
. O

 O
Surgical O
excision O
of O
the O
mass O
was O
performed O
without O
postoperative O
complications O
. O

 O
Grossly O
, O
the O
excised O
mass O
was O
a O
well O
- O
defined O
, O
ovoid O
, O
cystic O
mass O
gray O
- O
tan O
in O
color O
. O

 O
On O
section O
, O
it O
was O
found O
to O
be O
a O
unilocular O
cyst O
filled O
with O
whitish O
mucous O
material O
. O

 O
Microscopically O
, O
the O
mass O
was O
lined O
with O
ciliated O
pseudostratified O
columnar O
epithelium O
suggestive O
of O
respiratory O
type O
- O
mucosa O
( O
Fig.3 O
) O
. O

 O
There O
was O
nonspecific O
collagenous O
fibrosis O
around O
the O
cyst O
. O

 O
The O
differential O
diagnosis O
of O
subcutaneous O
cyst O
included O
epidermal O
inclusion O
cyst O
, O
thyroglossal O
duct O
cyst O
, O
branchial O
cleft O
cyst O
, O
and O
dermoid O
cyst O
. O

 O
There O
was O
no O
histological O
evidence O
of O
squamous O
epithelium O
, O
keratin O
, O
thyroid O
tissue O
, O
or O
skin O
appendage O
in O
the O
cystic O
wall O
of O
the O
present O
case O
. O

 O
The O
mass O
was O
diagnosed O
as O
a O
. O

An O
was O
for O
evaluation O
of O
. O

 O
He O
was O
born O
at O
term O
weighing O
4 O
  O
kg O
to O
and O
attained O
normal O
early O
developmental O
milestones O
. O

 O
Height O
and O
weight O
were O
on O
the O
10th O
and O
50th O
centiles O
, O
respectively O
. O

 O
Preliminary O
examination O
was O
remarkable O
only O
for O
hepatomegaly O
extending O
3.5 O
  O
cm O
below O
the O
right O
costal O
margin O
. O

 O
Initial O
laboratory O
evaluation O
revealed O
normochromic O
normocytic O
anaemia O
( O
haemoglobin O
7.8 O
  O
g O
/ O
dL O
( O
11.5–16 O
) O
, O
mean O
corpuscular O
volume O
( O
MCV O
) O
85.8 O
  O
fL O
( O
75–87 O
) O
and O
mean O
corpuscular O
haemoglobin O
( O
MCH O
) O
25.4 O
  O
pg O
( O
25–35 O
) O
) O
with O
marked O
anisocytosis O
( O
red O
- O
cell O
distribution O
width O
( O
RDW O
) O
29 O
% O
( O
11–14.5 O
) O
) O
. O

 O
Hypochromia O
and O
teardrops O
were O
evident O
on O
a O
blood O
film O
. O

 O
Leucopoenia O
was O
also O
a O
feature O
( O
white O
cell O
count O
2.9×109 O
/ O
L O
( O
4.5–13.5 O
) O
, O
neutrophils O
1.7×109 O
/ O
L O
( O
2–7.5 O
) O
and O
lymphocytes O
0.8×109 O
/ O
L O
( O
1.5–4 O
) O
) O
. O

 O
A O
bone O
marrow O
aspirate O
and O
biopsy O
revealed O
a O
hypercellular O
marrow O
with O
erythroid O
hyperplasia O
. O

 O
An O
iron O
stain O
revealed O
that O
approximately O
50 O
% O
of O
erythroblasts O
were O
ringed O
sideroblasts O
. O

 O
Marrow O
cytogenetics O
were O
normal O
including O
fluorescence O
in O
situ O
hybridisation O
studies O
of O
chromosomes O
5q O
, O
7 O
and O
8 O
and O
flow O
cytometry O
did O
not O
detect O
a O
blast O
population O
. O

 O
Serum O
copper O
and O
lead O
were O
normal O
, O
as O
were O
blood O
smears O
on O
the O
proband O
’s O
parents O
and O
sister O
. O

 O
Analysis O
of O
several O
genes O
responsible O
for O
hereditary O
SA O
( O
ALAS2 O
, O
ABC7 O
, O
FECH O
and O
PUS1 O
) O
revealed O
no O
reported O
pathogenic O
variants O
. O

 O
Fasting O
lactate O
was O
elevated O
at O
3.8 O
  O
mmol O
/ O
L. O

 O
Neurological O
examination O
identified O
upper O
motor O
neuron O
signs O
in O
the O
lower O
limbs O
bilaterally O
; O
however O
, O
cerebellar O
signs O
were O
negative O
. O

 O
MRI O
of O
the O
brain O
demonstrated O
volume O
loss O
with O
slight O
prominence O
of O
the O
cerebellar O
folia O
. O

 O
Urine O
organic O
acids O
revealed O
elevated O
3 O
- O
methylglutaconate O
and O
3 O
- O
methylglutarate O
. O

 O
The O
lactate O
: O
pyruvate O
ratio O
was O
elevated O
( O
30:1 O
) O
. O

 O
Muscle O
biopsy O
revealed O
a O
structurally O
normal O
muscle O
and O
biochemical O
assay O
of O
respiratory O
chain O
components O
resulted O
in O
a O
diagnosis O
of O
partial O
complex O
IV O
deficiency O
. O

 O
He O
subsequently O
commenced O
a O
high O
- O
fat O
diet O
and O
coenzyme O
Q O
with O
a O
resultant O
improvement O
in O
energy O
. O

 O
Analysis O
of O
mtDNA O
in O
leucocytes O
and O
muscle O
utilising O
PCR O
did O
not O
reveal O
a O
deletion O
. O

 O
Carnitine O
, O
vitamin O
A O
, O
thiamine O
, O
pyridoxine O
, O
folate O
and O
uridine O
were O
supplemented O
without O
improvement O
in O
his O
anaemia O
. O

 O
Haemoglobin O
levels O
fell O
to O
4.4 O
  O
g O
/ O
dL O
, O
leading O
to O
occasional O
and O
then O
regular O
three O
- O
weekly O
red O
cell O
transfusions O
. O

 O
With O
repeated O
transfusions O
, O
ferritin O
rose O
to O
1700 O
  O
µg O
/ O
L O
, O
necessitating O
iron O
chelation O
. O

 O
Peak O
growth O
hormone O
and O
cortisol O
to O
insulin O
- O
induced O
hypoglycaemia O
were O
30.9 O
  O
mU O
/ O
L O
( O
normal O
> O
20 O
) O
and O
447 O
  O
nmol O
/ O
L O
( O
normal O
> O
500 O
) O
, O
respectively O
, O
at O
age O
13 O
years O
. O

 O
Thyroid O
function O
was O
normal O
. O

 O
Repeat O
peak O
cortisol O
was O
384 O
  O
nmol O
/ O
L O
following O
adrenocorticotropic O
hormone O
( O
ACTH O
) O
stimulation O
. O

 O
Plasma O
renin O
activity O
was O
elevated O
to O
15 O
  O
ng O
/ O
mL O
/ O
h O
, O
and O
adrenal O
androgens O
were O
below O
the O
lower O
limit O
of O
assay O
detection O
. O

 O
A O
urinary O
steroid O
profile O
was O
qualitatively O
normal O
, O
as O
was O
an O
abdominal O
ultrasound O
. O

 O
Hydrocortisone O
5 O
  O
mg O
twice O
daily O
and O
fludrocortisone O
100 O
  O
µg O
daily O
were O
initiated O
. O

 O
Adrenal O
autoantibodies O
to O
21 O
- O
hydroxylase O
were O
negative O
and O
very O
- O
long O
- O
chain O
fatty O
acids O
were O
normal O
. O

 O
The O
patient O
has O
recently O
developed O
a O
renal O
tubular O
Fanconi O
syndrome O
including O
glycosuria O
, O
hypokalaemia O
, O
hypophosphataemia O
with O
low O
maximal O
tubular O
reabsorption O
of O
phosphate O
and O
a O
generalised O
aminoaciduria O
. O

 O
In O
addition O
, O
he O
was O
incidentally O
noted O
to O
have O
hyperglycaemia O
during O
an O
admission O
for O
percutaneous O
endoscopic O
gastrostomy O
insertion O
. O

 O
Glycated O
haemoglobin O
was O
elevated O
to O
62 O
  O
mmol O
/ O
mol O
( O
7.8 O
% O
) O
despite O
rapid O
red O
cell O
turnover O
. O

 O
Pancreatic O
autoantibodies O
were O
negative O
( O
glutamic O
acid O
decarboxylase O
, O
anti O
- O
insulin O
, O
anti O
- O
islet O
antigen O
2 O
and O
pancreatic O
islet O
cell O
antibodies O
) O
. O

 O
He O
is O
maintained O
on O
twice O
daily O
with O
satisfactory O
glycaemic O
control O
with O
( O
205–285 O
) O
. O

A O
presented O
to O
the O
with O
and O
a O
blocked O
left O
- O
sided O
nasal O
canal O
with O
for O
2 B
  I
years I
. O

 O
Medical O
history O
revealed O
secondary O
for O
the O
past O
19 B
  I
years I
with O
with O
no O
. O

 O
and O
were O
. O

 O
revealed O
a O
left O
- O
sided O
choanal O
. O

 O
As O
the O
was O
, O
was O
advised O
prior O
to O
performing O
a O
biopsy O
. O

 O
of O
the O
showed O
a O
sellar O
and O
infra O
- O
sellar O
( O
figure O
1 O
) O
. O

 O
The O
patient O
was O
then O
referred O
to O
the O
for O
further O
. O

 O
Her O
was O
very O
high—7443 O
  O
µg O
/ O
L O
( O
N<20 O
) O
. O

 O
were O
. O

 O
A O
final O
diagnosis O
of O
was O
made O
and O
the O
patient O
was O
prescribed O
with O
the O
associated O
risks O
explained O
in O
advance O
. O

A O
with O
a O
presented O
with O
an O
abnormal O
measuring O
in O
the O
imaged O
through O
chest O
( O
) O
scanning O
in O
in O
a O
. O

 O
He O
had O
. O

 O
suggested O
no O
significant O
. O

 O
were O
, O
except O
for O
a O
( O
) O
level O
of O
( O
normal O
range O
, O
0–5 O
  O
ng O
/ O
mL O
) O
found O
in O
the O
. O

 O
Subsequently O
, O
a O
( O
PET)/CT O
scan O
showed O
a O
lung O
with O
a O
of O
, O
which O
was O
highly O
suspected O
to O
be O
a O
( O
Fig.1 O
) O
. O

 O
Subsequently O
, O
he O
underwent O
left O
upper O
lung O
and O
. O

 O
Postoperative O
revealed O
an O
( O
) O
( O
Fig.2A O
) O
. O

 O
( O
) O
staining O
results O
were O
positive O
for O
, O
, O
, O
and O
and O
negative O
for O
, O
, O
, O
and O
( O
20%–30 O
% O
) O
. O

 O
The O
was O
classified O
as O
( O
) O
. O

 O
Because O
the O
was O
still O
in O
an O
early O
stage O
, O
the O
patient O
did O
not O
receive O
but O
continued O
to O
be O
through O
regular O
hospital O
. O

 O
The O
patient O
's O
had O
been O
until O
the O
onset O
of O
left O
chest O
in O
. O

 O
The O
patient O
was O
to O
our O
( O
a O
) O
for O
further O
treatment O
. O

 O
suggested O
a O
significant O
in O
the O
. O

 O
showed O
only O
a O
single O
parameter O
outside O
the O
normal O
range O
: O
the O
( O
) O
level O
was O
in O
the O
( O
normal O
range O
  O
= O
  O
0–3.3 O
  O
ng O
/ O
mL O
) O
. O

 O
and O
/ O
scans O
highlighted O
the O
serious O
of O
, O
showing O
bilateral O
lung O
( O
Fig.3A O
and O
E O
) O
. O

 O
At O
that O
point O
, O
the O
was O
to O
. O

 O
After O
the O
CT O
- O
guided O
left O
pleura O
, O
pathological O
showed O
positive O
staining O
for O
, O
, O
, O
and O
, O
while O
and O
staining O
were O
absent O
, O
supporting O
a O
diagnosis O
of O
( O
) O
( O
Fig.2B O
) O
. O

 O
Meanwhile O
, O
confirmed O
an O
in O
exon O
21 O
and O
a O
in O
( O
Fig.4B O
and O
C O
) O
. O

 O
. O

 O
( O
Fig.4A O
) O
. O

 O
To O
relieve O
the O
acute O
pain O
in O
the O
left O
pleura O
as O
quickly O
as O
possible O
, O
palliative O
( O
) O
for O
the O
chest O
lesion O
was O
delivered O
at O
a O
total O
dose O
of O
( O
f O
) O
, O
and O
( O
Fig.5 O
) O
. O

 O
The O
volume O
over O
radiation O
dose O
5 O
  O
Gy O
( O
V5 O
) O
values O
of O
the O
left O
, O
right O
, O
and O
total O
lungs O
were O
20 O
% O
, O
0 O
% O
, O
and O
7.8 O
% O
, O
respectively O
; O
the O
volume O
over O
radiation O
dose O
20 O
  O
Gy O
( O
V20 O
) O
values O
were O
10 O
% O
, O
0 O
% O
, O
and O
5 O
% O
, O
respectively O
; O
the O
mean O
lung O
dose O
( O
MLD O
) O
was O
5 O
  O
Gy O
. O

 O
Meanwhile O
, O
considering O
the O
MST O
pathology O
was O
that O
of O
SCC O
, O
the O
patient O
received O
GP O
chemotherapy O
( O
cisplatin O
75 O
  O
mg O
/ O
m2 O
d1 O
, O
gemcitabine O
1250 O
  O
mg O
/ O
m2 O
d1 O
, O
d8 O
, O
for O
21 O
days O
as O
a O
cycle O
) O
for O
4 O
cycles O
, O
and O
the O
patient O
achieved O
partial O
remission O
( O
PR O
) O
after O
2 O
cycles O
, O
followed O
by O
stable O
disease O
( O
SD O
) O
after O
4 O
cycles O
( O
Fig.3[B3[B O
and O
F O
] O
and O
[ O
C O
and O
G O
] O
) O
according O
to O
response O
evaluation O
criteria O
in O
solid O
tumors O
( O
RECIST O
) O
1.1 O
. O

 O
Then O
, O
( O
) O
was O
used O
as O
maintenance O
treatment O
onward O
. O

 O
During O
the O
treatment O
, O
was O
given O
for O
. O

 O
The O
patient O
is O
currently O
under O
surveillance O
with O
( O
Fig.3D O
and O
H O
) O
and O
with O
scores O
of O
. O

A O
who O
underwent O
was O
found O
to O
have O
a O
2 O
cm O
that O
was O
located O
from O
the O
and O
. O

 O
The O
polyp O
was O
a O
with O
focal O
. O

 O
A O
performed O
, O
as O
well O
as O
a O
repeat O
, O
were O
both O
for O
recurrence O
. O

 O
A O
performed O
revealed O
a O
, O
in O
size O
, O
at O
from O
the O
. O

 O
were O
taken O
and O
reported O
to O
be O
fragments O
of O
a O
with O
. O

 O
Due O
to O
the O
previous O
high O
- O
grade O
dysplasia O
, O
relatively O
rapid O
recurrence O
and O
concern O
that O
a O
cancer O
may O
have O
been O
missed O
by O
sampling O
error O
, O
a O
pelvic O
( O
) O
scan O
and O
an O
( O
) O
were O
performed O
before O
definitive O
excision O
. O

 O
The O
revealed O
an O
invasive O
rectal O
involving O
the O
but O
without O
breach O
of O
the O
adventitia O
, O
consistent O
with O
a O
( O
Figure O
1 O
) O
. O

 O
No O
pelvic O
was O
detected O
. O

 O
The O
revealed O
a O
rectal O
involving O
the O
and O
, O
with O
no O
involvement O
of O
the O
muscularis O
propria O
( O
Figure O
2 O
) O
. O

 O
The O
results O
of O
the O
MRI O
and O
EUS O
, O
as O
well O
as O
the O
surgical O
versus O
endoscopic O
resection O
treatment O
options O
, O
were O
discussed O
with O
the O
patient O
, O
who O
opted O
for O
a O
. O

 O
The O
patient O
underwent O
a O
and O
with O
. O

 O
of O
the O
revealed O
a O
with O
. O

 O
There O
was O
no O
evidence O
of O
, O
and O
a O
total O
of O
five O
pericolic O
and O
two O
mesorectal O
lymph O
nodes O
were O
excised O
and O
deemed O
benign O
. O

 O
The O
patient O
underwent O
. O

 O
He O
remains O
with O
no O
. O

A O
had O
been O
diagnosed O
with O
of O
the O
with O
bone O
at O
a O
. O

 O
The O
serum O
levels O
of O
and O
were O
, O
but O
brain O
revealed O
that O
his O
was O
. O

 O
However O
, O
of O
the O
revealed O
partial O
. O

 O
The O
was O
therefore O
determined O
to O
be O
. O

 O
The O
patient O
underwent O
with O
and O
, O
but O
the O
continuation O
of O
chemotherapy O
was O
. O

 O
Treatment O
for O
and O
caused O
by O
the O
was O
initiated O
, O
as O
was O
treatment O
with O
for O
bone O
. O

 O
The O
patient O
was O
to O
the O
due O
to O
a O
and O
the O
worsening O
of O
his O
. O

 O
A O
revealed O
, O
a O
subcutaneous O
that O
was O
in O
the O
, O
and O
and O
of O
the O
without O
, O
, O
, O
or O
. O

 O
The O
by O
in O
and O
was O
and O
his O
was O
. O

 O
Among O
the O
, O
the O
and O
counts O
, O
and O
, O
, O
and O
levels O
were O
found O
to O
be O
, O
and O
the O
patient O
's O
level O
was O
to O
2.8 O
mEq O
/ O
L. O

 O
The O
patient O
's O
( O
) O
, O
( O
) O
, O
( O
) O
, O
and O
( O
) O
levels O
were O
also O
. O

 O
The O
patient O
's O
was O
negative O
for O
, O
, O
and O
; O
a O
also O
yielded O
a O
result O
. O

 O
These O
data O
suggested O
that O
the O
increased O
production O
of O
ACTH O
by O
the O
tumor O
, O
along O
with O
the O
progression O
of O
the O
disease O
, O
had O
promoted O
the O
elevation O
of O
the O
patient O
's O
serum O
levels O
of O
ACTH O
and O
cortisol O
. O

 O
( O
) O
revealed O
the O
progression O
of O
the O
disease O
in O
the O
both O
thymic O
and O
metastatic O
bone O
, O
along O
with O
the O
multiple O
ground O
- O
glass O
in O
( O
Fig.1 O
, O
​2 O
) O
. O

 O
The O
patient O
underwent O
( O
) O
in O
the O
with O
, O
and O
. O

 O
The O
in O
the O
was O
, O
and O
the O
in O
the O
was O
, O
, O
and O
, O
with O
a O
. O

 O
, O
, O
and O
were O
all O
. O

 O
A O
revealed O
that O
the O
patient O
's O
was O
positive O
for O
. O

 O
was O
diagnosed O
based O
on O
the O
above O
results O
. O

 O
The O
patient O
was O
treated O
with O
( O
) O
for O
3 B
weeks I
. O

 O
with O
was O
also O
initiated O
at O
the O
same O
time O
with O
a O
to O
slowly O
correct O
the O
. O

 O
Intensive O
therapy O
, O
supplementation O
were O
initiated O
, O
while O
was O
administered O
to O
treat O
of O
the O
. O

 O
The O
patient O
's O
fully O
improved O
without O
the O
exacerbation O
of O
his O
. O

 O
Thereafter O
, O
we O
continued O
to O
administer O
at O
a O
. O

 O
The O
dosage O
was O
gradually O
increased O
from O
, O
and O
the O
value O
was O
observed O
to O
( O
Fig.3 O
) O
. O

 O
In O
order O
to O
prevent O
hypocortisolemia O
, O
the O
patient O
was O
temporarily O
treated O
with O
. O

 O
After O
an O
improvement O
of O
his O
left O
lower O
leg O
, O
, O
and O
, O
the O
patient O
underwent O
and O
for O
, O
which O
had O
been O
caused O
by O
a O
metastatic O
spinal O
. O

 O
therapy O
was O
initiated O
, O
and O
he O
was O
on O
the O
of O
hospitalization O
. O

In O
, O
a O
emergently O
with O
acute O
. O

 O
She O
had O
a O
1 B
- I
month I
history O
of O
progressive O
and O
a O
gradual O
decrease O
in O
secondary O
to O
mild O
. O

 O
She O
reported O
no O
. O

 O
At O
, O
she O
had O
been O
with O
a O
stage O
IIA O
, O
T1bN1 O
, O
left O
- O
sided O
. O

 O
Initial O
treatment O
had O
included O
a O
and O
axillary O
. O

 O
She O
subsequently O
underwent O
4 O
cycles O
of O
( O
) O
, O
followed O
by O
of O
, O
, O
and O
. O

 O
before O
and O
after O
showed O
normal O
. O

 O
After O
, O
she O
underwent O
left O
whole O
- O
breast O
with O
an O
. O

 O
Because O
the O
had O
been O
, O
her O
subsequent O
medical O
regimen O
consisted O
only O
of O
. O

 O
She O
took O
for O
5 B
years I
, O
and O
, O
ever O
since O
, O
the O
aromatase O
inhibitor O
. O

 O
In O
the O
17 B
years I
after I
chemotherapy O
, O
she O
had O
been O
and O
in O
relatively O
good O
. O

 O
In O
addition O
to O
her O
other O
symptoms O
, O
she O
now O
presented O
with O
, O
, O
and O
. O

 O
She O
had O
marked O
jugular O
venous O
, O
an O
, O
, O
and O
trace O
peripheral O
. O

 O
Initial O
were O
except O
for O
an O
elevated O
level O
of O
( O
) O
. O

 O
Results O
of O
investigation O
into O
the O
new O
- O
onset O
included O
normal O
levels O
, O
an O
( O
) O
that O
revealed O
no O
, O
and O
a O
coronary O
of O
appearance O
. O

 O
The O
showed O
sinus O
with O
frequent O
premature O
ventricular O
complexes O
, O
, O
left O
atrial O
, O
and O
low O
- O
voltage O
with O
nonspecific O
( O
Fig.1 O
) O
. O

 O
A O
2 O
- O
dimensional O
revealed O
a O
( O
) O
of O
, O
severe O
diffuse O
left O
ventricular O
( O
LV O
) O
, O
and O
a O
mildly O
. O

 O
To O
better O
define O
the O
cause O
of O
the O
LV O
systolic O
dysfunction O
, O
( O
) O
was O
performed O
. O

 O
It O
confirmed O
the O
of O
. O

 O
The O
showed O
slow O
flow O
secondary O
to O
LV O
, O
and O
no O
myocardial O
( O
Fig.2A O
) O
. O

 O
Late O
disclosed O
diffuse O
myocardial O
and O
no O
scarring O
( O
Fig.2B O
) O
. O

 O
The O
patient O
was O
. O

 O
Her O
progressively O
during O
, O
which O
consisted O
of O
a O
, O
an O
, O
, O
and O
a O
. O

 O
The O
was O
slowly O
, O
and O
her O
from O
to O
during O
an O
8 B
- I
month I
period I
. O

 O
All O
except O
for O
low O
- O
dose O
metoprolol O
were O
, O
and O
she O
remained O
. O

A O
with O
was O
to O
in O
to O
be O
for O
lung O
and O
kidney O
. O

 O
Patients O
with O
cystic O
fibrosis O
are O
known O
to O
develop O
chronic O
lung O
infections O
that O
adapt O
over O
time O
to O
this O
unique O
anatomic O
niche O
( O
14 O
, O
15 O
) O
. O

 O
His O
complicated O
medical O
history O
included O
, O
liver O
transplantation O
in O
2004 O
, O
steroid O
- O
induced O
diabetes O
, O
end O
- O
stage O
renal O
disease O
, O
and O
testicular O
cancer O
. O

 O
He O
had O
a O
long O
history O
of O
with O
several O
multidrug O
- O
resistant O
bacteria O
, O
including O
MRSA O
. O

 O
He O
was O
treated O
with O
ceftaroline O
at O
an O
outside O
hospital O
immediately O
prior O
to O
transfer O
to O
Houston O
Methodist O
Hospital O
. O

 O
The O
patient O
was O
periodically O
hospitalized O
from O
January O
to O
July O
2013 O
and O
was O
treated O
for O
recurrent O
respiratory O
and O
catheter O
- O
related O
infections O
caused O
by O
MRSA O
and O
multidrug O
- O
resistant O
Pseudomonas O
aeruginosa O
. O

 O
His O
antibiotic O
exposure O
included O
long O
treatment O
courses O
with O
various O
agents O
, O
including O
, O
, O
, O
, O
, O
, O
, O
and O
inhaled O
and O
systemic O
and O
. O

 O
Shortly O
after O
being O
to O
our O
in O
, O
was O
grown O
from O
of O
and O
. O

 O
These O
two O
were O
resistant O
to O
, O
, O
, O
and O
and O
susceptible O
to O
minocycline O
, O
rifampin O
, O
and O
. O

 O
His O
blood O
grew O
confluently O
around O
the O
, O
yielding O
an O
. O

 O
Five O
additional O
S. O
aureus O
respiratory O
tract O
were O
available O
for O
further O
study O
. O

 O
All O
MRSA O
isolates O
from O
this O
patient O
had O
a O
small O
- O
colony O
- O
variant O
( O
SCV O
) O
phenotype O
. O

A O
was O
to O
our O
due O
to O
congestive O
and O
ventricular O
in O
. O

 O
He O
had O
been O
suffering O
from O
and O
ventricular O
for B
years I
despite O
receiving O
the O
( O
ie O
, O
, O
, O
, O
, O
, O
and O
) O
. O

 O
His O
height O
was O
and O
body O
weight O
was O
. O

 O
was O
. O

 O
The O
was O
and O
was O
. O

 O
The O
chest O
showed O
with O
a O
of O
( O
figure O
1A O
) O
. O

 O
, O
as O
shown O
in O
video O
1 O
, O
revealed O
a O
diffused O
with O
markedly O
dilated O
( O
: O
) O
and O
reduced O
( O
) O
. O

 O
The O
coronary O
was O
. O

 O
A O
myocardial O
revealed O
that O
over O
50 O
% O
of O
cardiomyocytes O
were O
replaced O
by O
fibrosis O
( O
figure O
2 O
) O
. O

 O
An O
implantable O
cardioverter O
- O
defibrillator O
was O
implanted O
. O

 O
Due O
to O
the O
typical O
facial O
appearance O
and O
, O
he O
was O
referred O
to O
the O
. O

 O
The O
was O
8.2 O
ng O
/ O
ml O
and O
was O
. O

 O
demonstrated O
a O
in O
the O
. O

 O
Thus O
, O
he O
was O
diagnosed O
as O
. O

 O
He O
was O
treated O
with O
long O
- O
acting O
- O
release O
( O
LAR O
) O
for O
8 B
months I
. O

 O
Thereafter O
, O
he O
underwent O
in O
( O
figure O
3 O
) O
. O

 O
The O
plasma O
levels O
of O
GH O
and O
IGF-1 O
were O
decreased O
with O
octreotide O
LAR O
, O
but O
basal O
plasma O
levels O
of O
GH O
were O
always O
more O
than O
4 O
ng O
/ O
ml O
and O
plasma O
IGF-1 O
levels O
were O
above O
the O
appropriate O
age O
range O
( O
figure O
3 O
) O
. O

 O
After O
surgery O
, O
both O
plasma O
levels O
of O
GH O
and O
IGF-1 O
further O
decreased O
. O

 O
Basal O
plasma O
levels O
of O
GH O
were O
mostly O
less O
than O
0.5 O
ng O
/ O
ml O
and O
IGF-1 O
levels O
were O
within O
normal O
ranges O
( O
figure O
3 O
) O
. O

 O
With O
the O
treatment O
of O
LAR O
, O
the O
cardiac O
function O
improved O
partially O
( O
cardiothoracic O
ratio=0.58 O
; O
EF=0.20 O
in O
September O
2008 O
) O
. O

 O
After O
surgery O
, O
the O
cardiac O
function O
improved O
drastically O
( O
cardiothoracic O
ratio=0.47 O
; O
EF=0.55 O
in O
April O
2009 O
; O
figures O
1B O
and O
​and2B).2B O
) O
. O

 O
Frequency O
of O
ventricular O
arrhythmias O
decreased O
and O
was O
tapered O
off O
. O

The O
patient O
is O
an O
to O
due O
to O
adrenal O
crisis O
triggered O
by O
. O

 O
She O
has O
developed O
recurrent O
respiratory O
since O
, O
and O
failed O
to O
respond O
to O
multiple O
hepatitis O
B O
virus O
( O
HBV O
) O
. O

 O
Reduced O
serum O
and O
levels O
were O
discovered O
at O
when O
was O
initiated O
. O

 O
In O
addition O
, O
started O
from O
, O
and O
was O
noticed O
after O
. O

 O
Her O
history O
includes O
, O
which O
was O
confirmed O
to O
be O
by O
renal O
. O

 O
at O
admission O
revealed O
, O
oral O
, O
, O
and O
. O

 O
Facial O
or O
dental O
abnormalities O
was O
not O
noted O
. O

 O
She O
is O
the O
in O
her O
family O
. O

 O
. O

 O
Initial O
revealed O
remarkable O
and O
reduced O
of O
, O
, O
and O
( O
Table O
​(Table1).1 O
) O
. O

 O
, O
as O
well O
as O
of O
various O
were O
in O
, O
except O
increased O
. O

 O
( O
) O
and O
( O
) O
were O
. O

 O
When O
regular O
was O
suspended O
, O
her O
8:00 O
am O
serum O
was O
measured O
at O
, O
with O
< O
5.00 O
  O
pg O
/ O
mL. O

 O
Serum O
levels O
of O
other O
, O
as O
well O
as O
serum O
and O
urine O
were O
. O

 O
Both O
and O
were O
. O

 O
She O
had O
positive O
, O
with O
at O
5.9 O
  O
mmol O
/ O
L. O

 O
with O
suggested O
a O
normal O
. O

 O
She O
was O
diagnosed O
with O
, O
, O
and O
. O

 O
Symptoms O
of O
, O
, O
and O
cleared O
with O
and O
stress O
- O
dose O
treatment O
. O

 O
( O
) O
therapy O
was O
suggested O
but O
denied O
by O
the O
parents O
. O

 O
At O
her O
discharge O
, O
she O
reported O
no O
events O
during B
the I
previous I
year I
as O
she O
at O
and O
avoided O
. O

 O
Her O
was O
withdrawn O
discharge O
, O
and O
she O
has O
only O
received O
ever O
since O
. O

 O
done O
at O
the O
follow O
- O
up O
documented O
increased O
levels O
of O
and O
, O
while O
remained O
. O

 O
To O
assess O
her O
NK O
- O
cell O
activity O
, O
a O
was O
done O
following O
previously O
described O
method.[10,11 O
] O
Effector O
to O
target O
cell O
ratio O
was O
set O
at O
10:1 O
. O

 O
Less O
apoptosis O
of O
target O
cell O
line O
( O
12.43 O
% O
, O
reference O
range O
15.11–26.91 O
% O
) O
was O
observed O
when O
cocultured O
with O
patient O
's O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
, O
indicating O
a O
deficient O
NK O
- O
cell O
cytotoxicity O
. O

The O
proband O
( O
II-2 O
in O
Fig.2 O
) O
is O
a O
, O
who O
first O
presented O
to O
our O
and O
was O
referred O
to O
us O
because O
of O
her O
. O

 O
She O
has O
, O
first O
experienced O
syncope O
at O
the O
age O
of O
3 O
, O
and O
was O
diagnosed O
with O
. O

 O
She O
was O
treated O
with O
; O
however O
, O
she O
subsequently O
experienced O
several O
instances O
of O
. O

 O
At O
the O
, O
she O
had O
a O
event O
, O
and O
was O
suspected O
of O
having O
because O
of O
her O
congenital O
deafness O
and O
. O

 O
Her O
was O
diagnosed O
as O
an O
arrhythmic O
episode O
when O
she O
was O
aware O
of O
tachycardia O
and O
as O
epilepsy O
when O
she O
was O
not O
. O

 O
She O
also O
had O
a O
subarachnoid O
hemorrhage O
at O
the O
. O

 O
When O
she O
first O
at O
our O
, O
she O
was O
not O
taking O
, O
because O
of O
a O
history O
of O
, O
but O
was O
taking O
in O
addition O
to O
. O

 O
Her O
was O
found O
to O
be O
( O
) O
at O
and O
administration O
of O
was O
initiated O
. O

 O
She O
her O
baby O
( O
III-1 O
in O
Fig.2 O
) O
through O
at O
our O
at O
the O
. O

 O
, O
she O
her O
( O
III-2 O
in O
Fig.2 O
) O
through O
at O
our O
. O

 O
Despite O
administration O
of O
, O
her O
remained O
( O
at O
the O
age O
of O
37 O
, O
at O
) O
( O
Figs.2 O
and O
​3a O
) O
, O
which O
is O
not O
unexpected O
because O
treatment O
with O
beta O
- O
blockers O
in O
LQTS1 O
is O
not O
expected O
to O
overtly O
reduce O
QTc O
[ O
18 O
] O
. O

 O
However O
, O
she O
continued O
to O
experience O
occasional O
and O
finally O
underwent O
an O
( O
) O
operation O
at O
. O

 O
Subsequently O
, O
she O
is O
in O
a O
. O

 O
Because O
the O
proband O
was O
suspected O
of O
and O
had O
a O
, O
beta O
blockers O
were O
initiated O
and O
both O
children O
remain O
in O
( O
Figs.2 O
and O
3b O
, O
c O
) O
. O

 O
QTc O
of O
the O
( O
III-1 O
in O
Fig.2 O
) O
was O
measured O
as O
, O
while O
the O
QTc O
of O
his O
( O
III-2 O
) O
was O
. O

 O
. O

 O
There O
is O
no O
history O
of O
sudden O
unexplained O
syncope O
or O
death O
of O
children O
or O
adults O
in O
the O
, O
despite O
the O
prolonged O
QTc O
of O
the O
children O
. O

 O
Clinical O
evaluation O
and O
consultation O
of O
the O
proband O
and O
her O
family O
members O
were O
performed O
at O
. O

 O
Clinical O
phenotypes O
were O
deduced O
from O
the O
clinical O
history O
, O
physical O
examinations O
, O
and O
. O

 O
were O
collected O
from O
the O
proband O
and O
her O
family O
members O
following O
, O
and O
written O
informed O
consent O
was O
obtained O
prior O
to O
sample O
collection O
. O

 O
was O
isolated O
from O
according O
to O
established O
protocols O
at O
our O
laboratory O
[ O
19 O
] O
. O

 O
Entire O
coding O
exons O
, O
including O
the O
intronic O
boundaries O
of O
the O
genes O
, O
of O
KCNQ1 O
( O
NCBI O
ref O
: O
NM_000218 O
) O
and O
other O
LQT O
causative O
genes O
( O
KCNH2 O
, O
SCN5A O
, O
KCNE1 O
, O
KCNE2 O
, O
KCNJ2 O
, O
SCN4B O
, O
KCNJ5 O
) O
were O
amplified O
by O
( O
) O
, O
according O
to O
established O
protocols O
in O
our O
laboratory O
. O

 O
Briefly O
, O
was O
subjected O
to O
with O
( O
) O
and O
. O

 O
The O
amplicons O
were O
subjected O
to O
conventional O
with O
( O
) O
. O

 O
The O
sequence O
data O
were O
( O
) O
and O
( O
) O
. O

 O
was O
performed O
to O
screen O
all O
coding O
exons O
and O
the O
exon O
– O
intron O
boundaries O
of O
the O
( O
NCBI O
ref O
: O
NM_000218.2 O
, O
NP_000209.2 O
) O
with O
concurrent O
screening O
of O
other O
( O
) O
. O

 O
We O
detected O
a O
novel O
, O
NM_000218.2 O
: O
c.115 O
G O
  O
> O
  O
T O
( O
p. O
Glu39X O
, O
in O
exon O
1a O
) O
, O
in O
the O
KCNQ1 O
gene O
of O
the O
proband O
, O
as O
well O
as O
a O
( O
, O
p. O
Pro448Arg O
) O
( O
Additional O
file O
1 O
: O
Table O
S1 O
) O
. O

 O
of O
her O
( O
I-2 O
) O
and O
( O
III-1 O
and O
III-2 O
) O
revealed O
that O
they O
were O
( O
Fig.2 O
) O
. O

 O
Her O
( O
II-3 O
) O
was O
also O
screened O
and O
found O
to O
be O
( O
NM_000218.2 O
: O
c.1343C O
  O
> O
  O
G O
, O
p. O
Pro448Arg O
) O
. O

 O
, O
and O
we O
have O
concluded O
the O
homozygous O
nonsense O
variant O
in O
the O
proband O
is O
the O
cause O
of O
her O
. O

 O
The O
proband O
was O
negative O
for O
, O
including O
the O
KCNE1 O
gene O
( O
Additional O
file O
1 O
: O
Table O
S1 O
) O
. O

A O
man O
with O
chronic O
underwent O
allogeneic O
in O
. O

 O
The O
was O
mismatched O
at O
a O
single O
human O
leukocyte O
antigen O
allele O
( O
DQB1 O
) O
, O
and O
was O
T O
- O
cell O
depleted O
using O
in O
vivo O
alemtuzumab O
. O

 O
He O
engrafted O
on O
day O
12 O
after O
transplant O
. O

 O
Aside O
from O
persistent O
lymphopenia O
and O
diarrhea O
from O
norovirus O
infection O
, O
his O
posttransplant O
course O
was O
unremarkable O
until O
mid O
- O
October O
when O
he O
developed O
tinnitus O
and O
rapidly O
progressive O
sensorineural O
deafness O
, O
resulting O
in O
subtotal O
hearing O
loss O
bilaterally O
( O
> O
95 O
dB O
) O
over O
2–3 O
weeks O
. O

 O
Brain O
magnetic O
resonance O
imaging O
( O
MRI O
) O
was O
unremarkable O
, O
as O
was O
cerebrospinal O
fluid O
( O
CSF O
) O
analysis O
( O
4 O
leukocytes/µL O
with O
50 O
% O
neutrophils O
and O
50 O
% O
lymphocytes O
, O
6 O
red O
blood O
cells/µL O
, O
glucose O
2.4 O
mmol O
/ O
L O
[ O
normal O
range O
, O
2.2–4.7 O
mmol O
/ O
L O
] O
, O
protein O
61 O
mg O
/ O
dL O
[ O
normal O
range O
, O
15–45 O
mg O
/ O
L O
] O
, O
absence O
of O
oligoclonal O
bands O
) O
. O

 O
Viral O
polymerase O
chain O
reaction O
( O
PCR O
) O
testing O
of O
CSF O
was O
negative O
for O
enterovirus O
and O
herpesvirus O
infection O
. O

 O
The O
patient O
was O
treated O
empirically O
with O
high O
- O
dose O
valacyclovir O
, O
broad O
- O
spectrum O
antibiotics O
, O
and O
2 O
g O
/ O
kg O
intravenous O
immunoglobulin O
( O
IVIG O
) O
. O

 O
Despite O
these O
interventions O
, O
he O
developed O
new O
symptoms O
of O
central O
dyspnea O
, O
postural O
hypotension O
, O
nausea O
, O
and O
gradually O
worsening O
balance O
. O

 O
Repeat O
neurological O
assessment O
confirmed O
persistent O
vestibulocochlear O
dysfunction O
6 O
weeks O
after O
symptom O
onset O
. O

 O
By O
mid O
- O
December O
, O
the O
patient O
had O
become O
increasingly O
withdrawn O
, O
irritable O
, O
and O
intermittently O
agitated O
. O

 O
He O
remained O
lymphopenic O
( O
lymphocytes O
0.54 O
× O
106 O
/ O
μL O
[ O
normal O
range O
, O
1.2–3.6 O
× O
106 O
/ O
μL O
] O
) O
. O

 O
MRI O
scans O
of O
the O
brain O
were O
unremarkable O
, O
as O
was O
serum O
testing O
for O
antineuronal O
antibodies O
; O
an O
electroencephalogram O
revealed O
only O
diffuse O
encephalopathy O
. O

 O
Given O
continued O
suspicion O
for O
a O
viral O
etiology O
, O
the O
patient O
was O
treated O
with O
high O
- O
dose O
glucocorticoids O
and O
again O
with O
IVIG O
. O

 O
He O
began O
refusing O
fluids O
, O
food O
, O
and O
medication O
, O
and O
was O
detained O
under O
the O
UK O
Mental O
Health O
Act O
. O

 O
Repeat O
MRI O
scanning O
showed O
interval O
development O
of O
new O
, O
nonenhancing O
signal O
abnormalities O
in O
both O
thalami O
and O
midbrain O
with O
cranial O
nerve O
involvement O
but O
no O
meningeal O
enhancement O
( O
Figure O
​1A O
) O
. O

 O
Near O
the O
end O
of O
December O
, O
a O
frontal O
lobe O
biopsy O
was O
performed O
. O

 O
Histology O
revealed O
reactive O
gliosis O
and O
diffuse O
infiltration O
with O
CD3+/8 O
+ O
lymphocytes O
( O
Figure O
1B O
) O
. O

 O
Extensive O
microbiological O
testing O
of O
the O
biopsy O
tissue O
for O
an O
infectious O
etiology O
was O
negative O
( O
Supplementary O
Table O
1 O
) O
. O

 O
Given O
the O
absence O
of O
a O
diagnosis O
and O
the O
patient O
's O
progressive O
neurological O
deterioration O
, O
CSF O
and O
brain O
biopsy O
tissue O
were O
analyzed O
in O
January O
2014 O
by O
metagenomic O
next O
- O
generation O
sequencing O
( O
NGS O
) O
[ O
2 O
] O
. O

 O
NGS O
analysis O
of O
the O
brain O
biopsy O
, O
genome O
assembly O
, O
and O
in O
situ O
hybridization O
revealed O
findings O
of O
neuroinvasive O
astrovirus O
( O
AstV O
) O
infection O
. O

 O
Despite O
lack O
of O
approved O
therapies O
, O
the O
patient O
was O
treated O
with O
ribavirin O
and O
IVIG O
. O

 O
However O
, O
he O
did O
not O
respond O
to O
these O
interventions O
, O
and O
remained O
in O
a O
minimally O
conscious O
state O
following O
withdrawal O
of O
sedation O
in O
March O
2014 O
. O

 O
He O
eventually O
at O
the O
, O
the O
diagnosis O
and O
approximately O
onset O
of O
. O

A O
was O
to O
our O
for O
evaluation O
of O
stuttering O
chest O
for O
10 B
days I
, O
and O
he O
was O
a O
. O

 O
There O
was O
no O
positive O
finding O
from O
the O
relevant O
. O

 O
He O
has O
, O
and O
relevant O
genetic O
information O
. O

 O
His O
showed O
over O
( O
Figure O
​1 O
) O
. O

 O
showed O
90 O
% O
in O
the O
( O
) O
, O
which O
was O
( O
Figure O
2 O
) O
. O

 O
T O
- O
wave O
still O
inversion O
over O
leads O
V1 O
to O
V4 O
after O
the O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
( O
Figure O
​3 O
) O
. O

 O
The O
patient O
after O
the O
PCI O
in O
and O
in O
the O
because O
of O
a O
. O

 O
His O
demonstrated O
( O
Figure O
​4 O
) O
, O
and O
severe O
, O
remarkable O
. O

 O
Although O
several O
were O
used O
, O
still O
occurred O
on O
him O
for O
, O
each O
was O
preceded O
by O
a O
period O
of O
blood O
pressure O
fluctuation O
and O
burst O
out O
concomitantly O
at O
the O
peak O
of O
a O
. O

 O
The O
patient O
felt O
abdominal O
and O
his O
abdominal O
showed O
suspicious O
right O
adrenal O
gland O
. O

 O
Enhanced O
of O
conformed O
that O
there O
was O
a O
in O
accompanied O
by O
an O
upset O
level O
of O
( O
Figure O
5 O
) O
. O

 O
The O
tumor O
was O
removed O
by O
, O
and O
showed O
( O
Figure O
​6 O
) O
. O

 O
After O
the O
, O
the O
turned O
gradually O
. O

 O
There O
was O
no O
in O
( O
Figure O
​7 O
) O
. O

A O
with O
a O
history O
of O
presented O
with O
exertional O
and O
. O

 O
She O
was O
first O
diagnosed O
with O
nonischemic O
at O
, O
when O
she O
presented O
with O
symptoms O
of O
congestive O
and O
( O
) O
revealed O
severe O
left O
ventricular O
( O
) O
. O

 O
At O
that O
time O
, O
her O
was O
( O
normal O
range O
, O
25–69 O
μmol O
/ O
L O
) O
, O
and O
her O
was O
( O
normal O
range O
, O
16–60 O
μmol O
/ O
L O
) O
. O

 O
The O
cardiomyopathy O
was O
attributed O
to O
. O

 O
After O
5 B
months I
of O
therapy O
with O
, O
her O
and O
free O
carnitine O
had O
increased O
to O
and O
, O
respectively O
, O
and O
her O
left O
ventricular O
had O
normalized O
, O
with O
fractional O
shortening O
of O
. O

 O
At O
the O
current O
admission O
, O
the O
patient O
reported O
that O
, O
over O
the O
past O
10 O
years O
, O
she O
had O
only O
been O
intermittently O
compliant O
with O
her O
, O
and O
that O
, O
approximately O
, O
her O
total O
carnitine O
and O
levels O
had O
dropped O
to O
and O
, O
respectively O
. O

 O
She O
underwent O
followed O
by O
( O
) O
with O
gadolinium O
enhancement O
. O

 O
The O
TTE O
showed O
normal O
and O
mild O
, O
concentric O
( O
Fig.1 O
) O
. O

 O
Results O
of O
CMR O
confirmed O
normal O
and O
but O
showed O
focal O
increased O
at O
the O
( O
, O
) O
( O
Fig.2 O
) O
with O
patchy O
( O
Fig.3 O
) O
. O

 O
On O
the O
basis O
of O
the O
patient O
's O
family O
history O
of O
, O
, O
and O
, O
a O
dual O
- O
chamber O
was O
placed O
for O
primary O
prevention O
of O
from O
both O
and O
. O

A O
with O
underwent O
living O
- O
donor O
. O

 O
His O
had O
been O
for O
14 B
years I
. O

 O
He O
developed O
multifocal O
salmon O
- O
pink O
skin O
, O
and O
swelling O
and O
spontaneous O
in O
the O
and O
. O

 O
The O
symptoms O
had O
gradually O
expanded O
across O
the O
and O
. O

 O
He O
was O
to O
our O
for O
the O
evaluation O
of O
( O
) O
and O
multifocal O
( O
Fig.1 O
) O
. O

 O
admission O
, O
he O
had O
developed O
chronic O
. O

 O
His O
level O
was O
at O
with O
maintenance O
comprising O
( O
) O
, O
( O
) O
, O
and O
( O
) O
. O

 O
The O
tacrolimus O
trough O
concentration O
was O
6.3 O
ng O
/ O
mL. O

 O
The O
patient O
had O
been O
. O

 O
On O
admission O
, O
his O
was O
and O
his O
level O
was O
3.9 O
mg O
/ O
dL. O

 O
The O
patient O
was O
initially O
treated O
with O
( O
) O
. O

 O
Two O
days O
after O
the O
initiation O
of O
this O
therapy O
, O
he O
was O
. O

 O
, O
an O
automated O
( O
; O
) O
showed O
positivity O
for O
. O

 O
A O
colony O
obtained O
from O
the O
patient O
’s O
blood O
culture O
was O
analyzed O
by O
MALDI O
- O
TOF O
( O
; O
) O
. O

 O
The O
identification O
score O
was O
2.064 O
( O
> O
2.0 O
) O
, O
indicating O
accurate O
identification O
of O
( O
Fig.2 O
) O
. O

 O
Additional O
evaluation O
of O
the O
patient O
’s O
blood O
specifically O
for O

 O
by O
means O
of O
gyrase O
subunit O
B O
( O
gyrB)-targeted O
( O
) O
yielded O
results O
. O

 O
We O
performed O
gyrB O
- O
targeted O
using O
a O
. O

 O
We O
used O
to O
prevent O
contamination O
of O
gyrB O
- O
targeted O
PCR O
( O
Fig.3 O
) O
. O

 O
In O
addition O
, O
we O
performed O
of O
this O
strain O
, O
and O
the O
results O
were O
> O
99 O
% O
consistent O
with O
the O
existing O
sequence O
( O
Fig.4 O
) O
. O

 O
Given O
these O
results O
, O
we O
diagnosed O
the O
patient O
with O
H. O

 O
cinaedi O
with O
. O

 O
We O
of O
the O
, O
which O
resulted O
in O
identification O
of O
cluster O
B O
. O

 O
A O
obtained O
was O
positive O
for O

 O
, O
but O
a O
obtained O
was O
. O

 O
The O
patient O
’s O
gradually O
resolved O
. O

 O
The O
patient O
continued O
treatment O
for O
a O
total O
of O
6 B
weeks I
( O
in O
a O
for O
2 B
weeks I
and O
oral O
for O
4 B
weeks I
) O
, O
and O
he O
had O
no O
this O
therapy O
. O

 O
His O
was O
negative O
, O
although O
it O
was O
. O

 O
We O
did O
not O
apply O
in O
this O
case O
. O

A O
known O
for O
is O
to O
our O
clinic O
for O
recurrent O
for O
nearly B
50 I
years I
. O

 O
She O
has O
had O
recurrent O
since O
the O
age O
of O
16 O
when O
her O
was O
diagnosed O
. O

 O
and O
her O
mother O
passed O
away O
from O
an O
intracranial O
hemorrhage O
. O

 O
to O
presentation O
she O
had O
undergone O
a O
left O
- O
sided O
via O
a O
lateral O
approach O
. O

 O
This O
had O
significantly O
reduced O
the O
frequency O
of O
her O
and O
for O
several O
years O
her O
was O
with O
the O
use O
of O
low O
dose O
. O

 O
However O
, O
she O
was O
to O
our O
due O
to O
increased O
severity O
and O
frequency O
over B
the I
prior I
12 I
months I
necessitating O
more O
frequent O
. O

 O
At O
the O
time O
of O
the O
patient O
was O
concerned O
about O
daily O
severe O
left O
sided O
despite O
several O
months O
use O
of O
topical O
and O
oral O
. O

 O
She O
required O
intravenous O
and O
. O

 O
Her O
baseline O
at O
the O
time O
of O
our O
was O
( O
normal O
  O
= O
  O
120 O
– O
160 O
g O
/ O
L O
) O
. O

 O
Her O
[ O
17 O
] O
was O
( O
) O
. O

 O
On O
, O
she O
had O
multiple O
on O
her O
, O
, O
and O
. O

 O
Her O
revealed O
bilateral O
along O
the O
. O

 O
There O
was O
extensive O
along O
the O
entire O
with O
which O
any O
resulted O
in O
immediate O
profuse O
. O

 O
Given O
the O
severity O
of O
the O
patient O
’s O
epistaxis O
despite O
medical O
therapy O
, O
she O
was O
offered O
endoscopic O
left O
- O
sided O
. O

 O
The O
surgical O
goals O
were O
to O
improve O
her O
quality O
of O
life O
by O
reducing O
the O
number O
and O
severity O
of O
epistaxis O
episodes O
while O
diminishing O
the O
need O
for O
blood O
transfusions O
. O

 O
The O
patient O
was O
content O
with O
the O
treatment O
plan O
and O
agreed O
to O
undergo O
surgical O
intervention O
. O

 O
The O
was O
performed O
under O
general O
anesthesia O
with O
endotracheal O
. O

 O
The O
nasal O
cavity O
was O
by O
inserting O
pledgets O
soaked O
in O
topical O
( O
) O
placed O
in O
for O
decongestion O
. O

 O
Using O
a O
zero O
degree O
endoscope O
the O
residual O
STSG O
and O
mucosa O
of O
the O
left O
septum O
was O
that O
resulted O
in O
the O
expected O
significant O
diffuse O
. O

 O
Immediate O
was O
attained O
using O
a O
, O
( O
FloSeal O
Hemostatic O
Matrix O
; O
Baxter O
Healthcare O
Corporation O
, O
Deerfield O
, O
IL O
, O
USA O
) O
( O
Fig.1 O
) O
. O

 O
The O
( O
Fig.2 O
) O
measured O
approximately O
in O
. O

 O
A O
4 O
x O
2 O
cm O
split O
thickness O
from O
the O
, O
and O
then O
placed O
endoscopically O
. O

 O
As O
seen O
in O
Fig.3 O
, O
the O
was O
placed O
with O
an O
. O

 O
Finally O
, O
2 O
mL O
of O
( O
TISSEEL O
fibrin O
sealant O
, O
Baxter O
Healthcare O
Corporation O
, O
Deerfield O
, O
IL O
, O
USA O
) O
was O
then O
( O
Fig.4 O
) O
. O

 O
was O
not O
used O
post O
- O
operatively O
and O
the O
patient O
was O
. O

 O
Clinical O
surgery O
( O
Fig.5 O
) O
showed O
that O
the O
entire O
graft O
had O
taken O
and O
the O
left O
- O
sided O
had O
dramatically O
diminished O
. O

 O
The O
patient O
was O
very O
content O
with O
the O
results O
of O
the O
procedure O
. O

 O
At O
6 O
months O
, O
her O
baseline O
had O
improved O
to O
and O
she O
was O
requiring O
with O
her O
hematologist O
’s O
intent O
to O
stop O
the O
transfusions O
if O
her O
hemoglobin O
remained O
greater O
than O
100 O
g O
/ O
L. O

 O
Her O
at O
6 O
month O
follow O
up O
was O
( O
) O
. O

A O
to O
the O
hospital O
with O
worsening O
exertional O
associated O
with O
and O
lower O
extremity O
for O
3 B
  I
weeks I
. O

 O
She O
had O
a O
long O
- O
standing O
history O
of O
and O
documented O
with O
prior O
episodes O
of O
. O

 O
She O
was O
a O
and O
had O
family O
members O
with O
, O
and O
. O

 O
revealed O
a O
of O
, O
of O
, O
of O
, O
of O
and O
97 O
% O
on O

 O
She O
was O
at O
. O

 O
Her O
showed O
, O
inspiratory O
in O
, O
a O
laterally O
displaced O
and O
bipedal O
. O

 O
The O
showed O
left O
ventricular O
and O
inferolateral O
. O

 O
Chest O
revealed O
and O
mild O
pulmonary O
. O

 O
The O
and O
levels O
were O
but O
the O
was O
at O
826.5 O
  O
pg O
/ O
mL. O

 O
showed O
a O
with O
an O
( O
) O
of O
and O
mild O
right O
ventricular O
. O

 O
Coronary O
artery O
revealed O
normal O
. O

 O
at O
was O
chosen O
for O
diuresis O
. O

 O
She O
but O
still O
had O
, O
so O
we O
added O
. O

 O
Subsequently O
, O
and O
were O
included O
in O
the O
regimen O
. O

 O
Repeat O
chest O
showed O
resolution O
of O
pulmonary O
. O

 O
The O
patient O
's O
during O
her O
hospital O
stay O
did O
not O
show O
signs O
of O
nor O
. O

 O
She O
did O
not O
develop O
and O
was O
discharged O
home O
. O

A O
was O
found O
lying O
down O
after O
10–12 O
hours O
of O
. O

 O
She O
was O
taken O
to O
an O
outlying O
( O
) O
, O
and O
subsequently O
to O
our O
with O
and O
and O
for O
further O
management O
. O

 O
She O
had O
a O
past O
history O
of O
, O
congestive O
heart O
failure O
, O
controlled O
hypertension O
, O
and O
alcoholism O
. O

 O
She O
. O

 O
On O
, O
she O
had O
a O
of O
, O
of O
, O
, O
( O
) O
. O

 O
on O
showed O
a O
of O
, O
60 O
, O
61 O
mm O
/ O
Hg O
, O
29 O
mEq O
/ O
L O
, O
and O
which O
improved O
to O
with O
by O
a O
. O

 O
On O
she O
was O
, O
, O
, O
but O
without O
. O

 O
Scattered O
were O
noted O
along O
with O
normal O
. O

 O
The O
remaining O
results O
of O
her O
physical O
examination O
and O
routine O
were O
with O
the O
exception O
of O
a O
of O
with O
. O

 O
Repeated O
were O
consistent O
with O
a O
normal O
but O
evidence O
of O
in O
the O
monitor O
. O

 O
Repeated O
on O
the O
showed O
: O
7.22 O
, O
78 O
, O
140 O
mm O
Hg O
, O
30 O
mEq O
/ O
L O
, O
and O
. O

 O
In O
the O
she O
was O
started O
on O
IV O
and O
for O
a O
. O

 O
As O
part O
of O
the O
, O
she O
underwent O
a O
chest O
that O
did O
not O
show O
any O
or O
any O
major O
. O

 O
The O
was O
only O
significant O
for O
sinus O
. O

 O
Given O
the O
negative O
findings O
on O
chest O
x O
ray O
, O
sinus O
tachycardia O
on O
ECG O
, O
and O
an O
increased O
A O
- O
a O
gradient O
, O
the O
patient O
was O
sent O
for O
a O
spiral O
chest O
to O
rule O
out O
a O
pulmonary O
. O

 O
During O
about O
100–150 O
mL O
of O
air O
was O
inadvertently O
injected O
through O
the O
using O
a O
( O
estimated O
by O
the O
technician O
and O
approximation O
of O
volumes O
on O
available O
imaging O
) O
. O

 O
Concurrent O
( O
CT O
) O
showed O
a O
significant O
in O
the O
and O
( O
Figure O
1 O
) O
, O
and O
in O
the O
and O
its O
( O
Figure O
2 O
) O
. O

 O
Concurrently O
, O
a O
filling O
defect O
was O
noted O
in O
the O
right O
lower O
lobe O
artery O
consistent O
with O
pulmonary O
( O
Figures O
3 O
, O
​,4).4 O
) O
. O

 O
The O
patient O
maintained O
with O
, O
and O
( O
) O
, O
and O
alone O
and O
she O
was O
to O
the O
( O
) O
for O
observation O
. O

 O
Her O
worsened O
, O
and O
she O
was O
placed O
temporarily O
on O
( O
) O
without O
and O
she O
was O
and O
placed O
on O
. O

 O
Intravenous O
full O
dose O
( O
) O
was O
initiated O
for O
treatment O
of O
concurrent O
. O

 O
did O
not O
show O
any O
evidence O
of O
. O

 O
Subsequent O
done O
did O
not O
show O
any O
evidence O
of O
intracardiac O
and O
complete O
resolution O
of O
the O
air O
. O

 O
During B
the I
next I
48 I
hours I
, O
she O
remained O
with O
no O
requirements O
of O
. O

 O
She O
was O
finally O
. O

 O
She O
was O
later O
on O
with O
subsequent O
outpatient O
. O

A O
of O
was O
at O
by O
. O

 O
His O
( O
primipara O
, O
) O
had O
been O
to O
our O
because O
of O
reduced O
and O
. O

 O
The O
child O
’s O
was O
( O
) O
, O
, O
and O
( O
25th O
percentile O
) O
. O

 O
He O
had O
and O
. O

 O
were O
, O
, O
and O
at O
1 O
, O
5 O
, O
and O
10 O
minutes O
. O

 O
The O
child O
presented O
with O
severe O
and O
, O
requiring O
and O
. O

 O
Weaning O
failed O
because O
of O
inadequate O
pulmonary O
ventilation O
and O
. O

 O
was O
detected O
by O
, O
while O
cranial O
showed O
and O
. O

 O
, O
the O
infant O
presented O
with O
severe O
with O
a O
. O

 O
revealed O
marked O
without O
. O

 O
showed O
hypoglycemia O
( O
) O
, O
( O
) O
, O
and O
hypokalemia O
( O
) O
. O

 O
was O
normal O
( O
, O
normal O
range O
0.5–2.2 O
mmol O
/ O
L O
) O
and O
were O
. O

 O
A O
skeletal O
muscle O
was O
performed O
and O
showed O
scattered O
, O
hypertrophic O
cytochrome O
c O
oxidase O
( O
COX)-deficient O
and O
succinate O
dehydrogenase O
– O
positive O
muscle O
fibers O
( O
figure O
) O
, O
suggesting O
a O
. O

 O
revealed O
marked O
in O
muscle O
( O
as O
) O
, O
while O
a O
within O
and O
COX O
- O
deficient O
fibers4 O
was O
. O

 O
We O
the O
entire O
coding O
region O
and O
intron O
- O
exon O
boundaries O
of O
the O
, O
identifying O
two O
reported O
in O
compound O
and O
c.2542G O
> O
A O
predicting O
p. O
G848S. O

 O
confirmed O
. O

 O
The O
infant O
at O
of O
. O

 O
At O
, O
the O
brain O
did O
not O
show O
remarkable O
changes O
on O
. O

 O
was O
not O
informative O
due O
to O
poor O
preservation O
of O
tissue O
; O
there O
was O
no O
evidence O
of O
in O
the O
. O

 O
The O
liver O
showed O
diffuse O
, O
consistent O
with O
total O
parenteral O
nutrition O
; O
hepatocyte O
, O
, O
or O
liver O
were O
not O
observed O
. O

 O
The O
testicles O
were O
undescended O
, O
while O
remaining O
visceral O
organs O
were O
normal O
except O
for O
a O
marked O
and O
of O
the O
. O

 O
Despite O
normal O
histology O
, O
analysis O
of O
stomach O
, O
ileum O
, O
and O
colon O
homogenates O
revealed O
severe O
( O
; O
table O
e-1 O
on O
the O
Neurology O
® O
Web O
site O
at O
www.neurology.org O
) O
. O

 O
Laser O
capture O
microdissection O
analysis5 O
revealed O
that O
the O
was O
confined O
to O
the O
, O
being O
most O
prominent O
in O
its O
( O
figure O
) O
. O

 O
Ganglion O
cells O
from O
the O
myenteric O
plexus O
showed O
milder O
, O
restricted O
to O
the O
( O
figure O
) O
. O

 O
There O
was O
no O
in O
( O
not O
shown O
) O
. O

A O
had O
been O
suffering O
from O
and O
severe O
for O
several B
months I
. O

 O
His O
were O
( O
normal O
range O
: O
12–16 O
g O
/ O
dl O
) O
. O

 O
He O
had O
and O
. O

 O
and O
did O
not O
reveal O
any O
significant O
. O

 O
Abdominal O
revealed O
a O
2 O
- O
cm O
hypervascular O
in O
the O
( O
Fig.1 O
) O
. O

 O
Oral O
detected O
a O
2 O
- O
cm O
- O
diameter O
reddish O
, O
submucosal O
tumor O
- O
like O
with O
surface O
ulceration O
in O
the O
, O
approximately O
( O
Fig.2 O
) O
. O

 O
We O
did O
not O
perform O
because O
it O
can O
be O
difficult O
to O
stop O
bleeding O
in O
the O
case O
of O
hypervascular O
lesions O
. O

 O
Under O
the O
diagnosis O
of O
a O
small O
bowel O
tumor O
, O
gastrointestinal O
stromal O
tumor O
( O
GIST O
) O
, O
malignant O
lymphoma O
, O
or O
cancer O
, O
we O
performed O
laparoscopic O
- O
assisted O
segmental O
of O
the O
with O
the O
. O

 O
Examination O
of O
the O
resected O
tumor O
showed O
that O
it O
measured O
in O
diameter O
( O
Fig.3 O
) O
. O

 O
revealed O
the O
proliferation O
of O
blood O
capillaries O
and O
granulation O
tissue O
, O
which O
was O
consistent O
with O
( O
Fig.4 O
) O
. O

 O
The O
patient O
was O
on O
without O
and O
his O
gradually O
without O
the O
need O
for O
after O
surgery O
. O

A O
at O
the O
, O
12 O
h O
after O
of O
a O
with O
tanning O
spray O
into O
his O
. O

 O
A O
plain O
abdominal O
( O
Figure O
1 O
) O
showed O
the O
container O
in O
the O
rectosigmoid O
region O
. O

 O
There O
were O
no O
signs O
of O
. O

 O
A O
flexible O
was O
performed O
under O
. O

 O
The O
was O
located O
just O
. O

 O
The O
could O
not O
be O
by O
. O

 O
An O
attempt O
to O
the O
object O
with O
, O
such O
as O
, O
was O
. O

 O
The O
could O
be O
passed O
alongside O
the O
to O
its O
proximal O
end O
. O

 O
A O
guide O
wire O
was O
left O
behind O
with O
the O
sigmoidoscope O
removed O
. O

 O
Subsequently O
, O
a O
40 O
mm O
( O
Rigiflex O
® O
, O
Boston O
Scientific O
) O
, O
normally O
used O
in O
achalasia O
patients O
, O
was O
inserted O
over O
the O
guide O
wire O
and O
inflated O
just O
above O
the O
( O
Figure O
2 O
) O
. O

 O
For O
safety O
purposes O
, O
the O
was O
reintroduced O
alongside O
the O
catheter O
of O
the O
to O
allow O
endoscopic O
visual O
control O
of O
the O
distal O
end O
of O
the O
in O
the O
. O

 O
Gentle O
traction O
was O
exerted O
on O
the O
catheter O
, O
and O
the O
was O
successfully O
under O
( O
Figure O
​3 O
) O
. O

A O
with O
a O
history O
of O
( O
) O
underwent O
bone O
marrow O
transplantation O
from O
his O
HLA O
- O
haploidentical O
mother O
in O
. O

 O
The O
conditioning O
regimens O
consisted O
of O
and O
( O
BUCY+ATG O
) O
( O
10 O
) O
. O

 O
( O
CsA O
) O
and O
short O
- O
term O
( O
) O
plus O
( O
) O
were O
used O
as O
prophylaxis O
against O
( O
) O
( O
11 O
) O
. O

 O
Standard O
measures O
were O
adopted O
for O
the O
prevention O
of O
, O
which O
included O
for O
antifungal O
and O
to O
prevent O
herpes O
- O
related O
. O

 O
A O
revealed O
the O
reconstruction O
of O
granulocytes O
( O
ANC>0.5×109 O
/ O
L O
) O
on O
day O
+12 O
post O
- O
transplantation O
. O

 O
The O
patient O
developed O
grade O
II O
acute O
of O
the O
skin O
on O
day O
+42 O
post O
- O
transplantation O
. O

 O
This O
was O
treated O
by O
treatment O
with O
a O
standard O
- O
dose O
of O
methyl O
- O
prednisolone O
, O
which O
achieved O
a O
complete O
response O
( O
CR O
) O
. O

 O
The O
patient O
's O
chronic O
GVHD O
( O
cGVHD O
) O
of O
the O
skin O
gradually O
progressed O
from O
day O
+100 O
post O
- O
transplantation O
and O
he O
was O
treated O
with O
prednisolone O
and O
CsA. O

 O
On O
day O
120 O
post O
- O
transplantation O
, O
he O
complained O
of O
a O
cough O
and O
antibiotics O
were O
administered O
. O

 O
A O
blood O
analysis O
revealed O
the O
following O
: O
WBC O
, O
2.34×109 O
/ O
L O
; O
ANC O
, O
1.72×109 O
/ O
L O
; O
hemoglobin O
, O
85 O
g O
/ O
L O
; O
and O
platelets O
, O
72×109 O
/ O
L. O

 O
Although O
both O
a O
chest O
computed O
tomography O
( O
CT O
) O
scan O
and O
tests O
for O
pathogens O
via O
routine O
culturing O
, O
including O
blood O
tests O
for O
Beta O
- O
D O
glucan O
( O
G O
- O
test O
) O
and O
Galactomannan O
( O
GM O
- O
test O
) O
were O
all O
negative O
, O
the O
patient O
's O
cough O
did O
not O
respond O
to O
antibiotics O
and O
we O
empirically O
initiated O
treatment O
with O
voriconazole O
( O
6 O
mg O
/ O
kg/12h O
for O
the O
first O
day O
, O
followed O
by O
4 O
mg O
/ O
kg/12h O
) O
. O

 O
Liver O
toxicity O
occurred O
during O
voriconazole O
treatment O
, O
thus O
the O
anti O
- O
fungal O
regimen O
was O
changed O
to O
micafungin O
( O
100 O
mg O
/ O
d O
) O
. O

 O
However O
, O
the O
persistent O
cough O
did O
not O
improve O
and O
hoarseness O
developed O
after O
two O
weeks O
of O
treatment O
- O
ulcers O
were O
then O
observed O
in O
the O
throat O
by O
laryngoscopy O
( O
Fig.1a O
) O
. O

 O
The O
patient O
developed O
severe O
dyspnea O
in O
the O
following O
week O
when O
anti O
- O
infection O
and O
topical O
treatments O
were O
applied O
. O

 O
Fiberoptic O
bronchoscopy O
revealed O
an O
irregular O
, O
nodular O
material O
with O
white O
moss O
, O
which O
nearly O
obstructed O
the O
bronchus O
; O
however O
, O
chest O
CT O
imaging O
was O
negative O
( O
Fig.1b O
and O
c O
) O
. O

 O
The O
histopathological O
examination O
of O
biopsy O
specimens O
revealed O
an O
Aspergillus O
species O
( O
Fig.1d O
) O
. O

 O
The O
patient O
was O
diagnosed O
with O
pseudomembranous O
Aspergillus O
tracheobronchitis O
type O
ITBA O
based O
on O
the O
results O
of O
bronchoscopy O
and O
a O
pathological O
examination O
( O
12 O
) O
. O

 O
The O
antibiotic O
and O
micafungin O
treatments O
were O
ceased O
and O
liposomal O
amphotericin O
B O
( O
liposomal O
AmB O
) O
was O
administered O
daily O
at O
a O
target O
dose O
of O
3 O
mg O
/ O
kg O
. O

 O
The O
patient O
's O
serum O
creatinine O
level O
rose O
from O
60.4 O
μmol O
/ O
L O
to O
168 O
μmol O
/ O
L O
during O
the O
first O
7 O
days O
of O
liposomal O
AmB O
treatment O
. O

 O
Due O
to O
progressive O
renal O
dysfunction O
, O
the O
anti O
- O
fungal O
regimen O
was O
switched O
to O
a O
combination O
of O
posaconazole O
( O
400 O
mg/12 O
h O
) O
and O
caspofungin O
[ O
50 O
mg O
, O
daily O
( O
70 O
mg O
for O
the O
first O
dose O
) O
] O
. O

 O
The O
combination O
therapy O
continued O
for O
2 O
weeks O
, O
until O
the O
previous O
nodules O
in O
the O
throat O
completely O
disappeared O
under O
bronchoscopy O
( O
Fig.2a O
) O
; O
however O
, O
a O
repeat O
chest O
CT O
scan O
showed O
progression O
( O
Fig.2b O
) O
. O

 O
The O
symptom O
of O
dyspnea O
gradually O
progressed O
, O
thus O
fiberoptic O
bronchoscopy O
was O
performed O
to O
remove O
the O
obstructive O
material O
from O
the O
patient O
's O
airways O
once O
a O
week O
for O
two O
weeks O
. O

 O
All O
of O
the O
symptoms O
were O
relieved O
and O
the O
final O
chest O
CT O
scan O
showed O
negative O
results O
before O
the O
discontinuation O
of O
anti O
- O
fungal O
therapy O
, O
and O
all O
of O
the O
tests O
were O
negative O
for O
Aspergillus O
. O

 O
Posaconazole O
was O
administered O
as O
a O
secondary O
prophylactic O
treatment O
and O
the O
patient O
was O
discharged O
from O
hospital O
. O

 O
The O
patient O
is O
still O
being O
and O
remains O
free O
of O
any O
recurrence O
of O
invasive O
fungal O
. O

An O
with O
. O

 O
Speech O
was O
normal O
and O
there O
was O
not O
any O
of O
. O

 O
Also O
, O
there O
was O
. O

 O
The O
family O
history O
was O
significant O
as O
. O

 O
and O
there O
was O
. O

 O
The O
was O
normal O
and O
her O
was O
30/30 O
. O

 O
and O
were O
normal O
. O

 O
The O
including O
, O
were O
normal O
, O
and O
no O
or O
were O
noticed O
. O

 O
The O
and O
were O
normal O
in O
; O
however O
, O
there O
was O
generalised O
exaggeration O
of O
myotatic O
reflexes O
along O
with O
. O

 O
and O
were O
intact O
but O
was O
positive O
. O

 O
Patient O
while O
. O

 O
Fasting O
and O
postprandial O
blood O
glucose O
levels O
were O
normal O
. O

 O
, O
, O
and O
were O
normal O
. O

 O
and O
levels O
were O
within O
normal O
limits O
. O

 O
showed O
absent O
sensory O
nerve O
action O
potential O
with O
normal O
distal O
latency O
, O
conduction O
velocity O
and O
amplitude O
of O
compound O
muscle O
action O
potential O
( O
CMAP O
) O
in O
all O
nerves O
trunks O
. O

 O
showed O
marked O
of O
the O
as O
compared O
to O
which O
was O
normal O
( O
figure O
1 O
) O
. O

 O
The O
using O
disclosed O
in O
. O

 O
A O
variety O
of O
causes O
of O
autosomal O
recessive O
ataxias O
need O
to O
be O
considered O
in O
the O
differential O
diagnosis O
of O
FRDA O
. O

 O
These O
were O
systemically O
excluded O
here O
. O

 O
( O
AVED O
) O
has O
a O
phenotype O
quite O
similar O
to O
FRDA O
, O
though O
and O
are O
more O
common O
in O
AVED.4 O
A O
favoured O
. O

 O
( O
) O
types O
1 O
and O
2 O
were O
not O
considered O
owing O
to O
lack O
of O
, O
( O
severe O
) O
, O
of O
and O
involuntary O
movements.5 O
has O
presentation O
very O
similar O
to O
AOA O
types O
1 O
and O
2 O
. O

 O
, O
sino O
- O
pulmonary O
, O
and O
along O
with O
predisposition O
to O
development O
of O
a O
variety O
of O
are O
features O
of O
ataxia O
telengiectasia O
not O
seen O
in O
AOAs O
and O
FRDA O
. O

 O
The O
other O
important O
causes O
of O
autosomal O
recessive O
spastic O
ataxia O
apart O
from O
FRDA O
would O
be O
and O
. O

 O
, O
an O
inherited O
polyneuropathy O
has O
in O
common O
with O
FRDA O
; O
however O
, O
in O
this O
case O
, O
was O
improbable O
due O
to O
following O
features O
in O
this O
case O
: O
lack O
of O
, O
retained O
reflexes O
, O
bilaterally O
extensor O
plantar O
and O
pure O
sensory O
neuropathy O
on O
nerve O
conduction O
study O
. O

 O
was O
started O
at O
a O
dose O
of O
for O
its O
antioxidant O
properties O
. O

 O
For O
gait O
ataxia O
, O
— O
— O
was O
initiated O
. O

 O
is O
monitored O
regularly O
. O

 O
At O
, O
there O
was O
no O
significant O
change O
in O
the O
. O

The O
patient O
was O
a O
of O
. O

 O
His O
height O
was O
and O
his O
. O

 O
Both O
parents O
were O
of O
normal O
height O
and O
neither O
showed O
any O
minor O
anomalies O
of O
the O
EvC O
syndrome O
spectrum O
. O

 O
The O
patient O
had O
two O
healthy O
. O

 O
His O
were O
: O
( O
a O
) O
normal O
mouth O
opening O
with O
missing O
lower O
incisors O
( O
Fig.1 O
) O
; O
( O
b O
) O
small O
chest O
, O
as O
determined O
by O
a O
; O
and O
( O
c O
) O
disproportionately O
short O
extremities O
with O
one O
additional O
postaxial O
digit O
on O
each O
hand O
( O
Fig.2 O
) O
. O

 O
Although O
no O
was O
noted O
, O
the O
patient O
presented O
with O
mild O
. O

 O
in O
his O
early O
infancy O
showed O
a O
previously O
reported O
homozygous O
nonsense O
mutation O
c.1195 O
C1 O
T O
, O
p. O
Arg399X O
of O
EvC2 O
, O
resulting O
in O
loss O
of O
function O
of O
the O
protein.(5 O
) O
His O
were O
of O
the O
. O

 O
In O
, O
the O
patient O
underwent O
successful O
ostium O
primum O
through O
a O
. O

 O
He O
with O
embolic O
cerebral O
in O
, O
and O
cavotricuspid O
isthmus O
for O
common O
was O
performed O
successfully O
. O

 O
There O
were O
no O
serious O
. O

 O
During O
a O
routine O
in O
, O
a O
high O
- O
pitched O
systolic O
was O
discovered O
. O

 O
showed O
sinus O
rhythm O
with O
hemiblock O
and O
, O
while O
revealed O
a O
and O
. O

 O
These O
abnormalities O
produced O
a O
flow O
that O
was O
directed O
to O
the O
left O
atrial O
appendage O
, O
leading O
to O
severe O
. O

 O
The O
patient O
’s O
systolic O
was O
and O
his O
. O

 O
His O
medical O
treatment O
included O
, O
, O
and O
. O

 O
The O
patient O
was O
scheduled O
for O
. O

 O
In O
the O
operating O
theatre O
, O
the O
patient O
’s O
right O
femoral O
artery O
was O
. O

 O
A O
right O
was O
performed O
on O
the O
and O
bicaval O
was O
established O
. O

 O
. O

 O
The O
operation O
used O
a O
normothermic O
. O

 O
To O
avoid O
air O
embolisms O
, O
was O
applied O
using O
a O
( O
) O
. O

 O
The O
attempt O
to O
perform O
a O
was O
unsuccessful O
and O
a O
bileaflet O
mechanical O
valve O
( O
no.29 O
) O
was O
. O

 O
No O
occurred O
. O

 O
The O
patient O
’s O
was O
and O
he O
was O
on O
. O

 O
After O
two O
years O
of O
, O
revealed O
of O
the O
and O
a O
decrease O
in O
systolic O
( O
) O
. O

A O
with O
a O
chief O
complaint O
of O
in O
. O

 O
He O
was O
diagnosed O
with O
in O
early O
childhood O
. O

 O
He O
was O
born O
at O
term O
with O
normal O
birth O
weight O
. O

 O
There O
was O
. O

 O
This O
patient O
had O
characteristic O
features O
of O
achondroplasia O
( O
i.e. O
, O
short O
stature O
, O
lumbar O
lordosis O
, O
short O
proximal O
long O
bones O
, O
large O
hands O
, O
frontal O
bossing O
, O
and O
flat O
nasal O
bridge O
) O
[ O
Figure O
1 O
] O
. O

 O
His O
height O
was O
. O

 O
Best O
corrected O
was O
in O
the O
with O
and O
in O
the O
with O
: O
. O

 O
Pupils O
were O
equal O
in O
size O
, O
round O
and O
reactive O
to O
light O
with O
no O
reverse O
afferent O
pupillary O
defect O
. O

 O
was O
in O
and O
was O
. O

 O
The O
was O
12 O
mm O
Hg O
by O
. O

 O
of O
the O
and O
left O
eyes O
were O
, O
and O
557 O
, O
respectively O
. O

 O
revealed O
a O
well O
- O
demarcated O
circular O
macular O
in O
. O

 O
In O
the O
right O
eye O
, O
this O
was O
approximately O
2.5 O
disc O
diameters O
( O
DD O
) O
in O
width O
and O
2.7 O
DD O
in O
length O
. O

 O
In O
the O
left O
eye O
, O
this O
was O
approximately O
and O
. O

 O
The O
border O
of O
the O
was O
. O

 O
Underlying O
choroidal O
and O
overlying O
retinal O
appeared O
. O

 O
In O
addition O
, O
a O
emanated O
and O
coursed O
[ O
Figure O
2 O
] O
. O

 O
Fluorescein O
of O
the O
and O
of O
the O
( O
Stratus O
; O
Carl O
Zeiss O
GmbH O
, O
Jena O
, O
Germany O
) O
were O
performed O
[ O
Figures O
​[Figures3 O
and O
4 O
] O
. O

 O
Due O
to O
the O
background O
maculopathy O
, O
the O
patient O
could O
not O
appropriately O
fixate O
on O
the O
target O
during O
image O
acquisition O
resulting O
in O
slightly O
decentered O
fluorescein O
angiography O
images O
[ O
Figure O
3 O
] O
. O

A O
was O
initially O
19 O
months O
prior O
to O
the O
current O
presentation O
, O
at O
which O
time O
fluorescein O
and O
indocyanine O
green O
angiography O
showed O
a O
medium O
- O
sized O
subfoveal O
classic O
in O
the O
, O
which O
had O
. O

 O
She O
did O
not O
return O
for O
until O
the O
current O
presentation O
, O
when O
she O
noted O
in O
the O
. O

 O
The O
( O
) O
was O
. O

 O
showed O
a O
small O
yellowish O
in O
the O
and O
. O

 O
Structural O
revealed O
the O
, O
and O
a O
hyper O
- O
reflective O
indicating O
type O
II O
. O

 O
with O
intravitreal O
were O
administered O
with O
a O
. O

 O
( O
Fig.1 O
) O
showed O
noticeable O
reduction O
in O
by O
injection O
, O
with O
at O
. O

 O
and O
were O
, O
probably O
due O
to O
the O
decreased O
flow O
or O
temporary O
closure O
of O
the O
smaller O
anastomoses O
. O

 O
Significant O
re O
- O
appearance O
of O
was O
noticeable O
at O
after O
the O
first O
injection O
and O
again O
at O
after O
the O
second O
injection O
. O

 O
The O
vascular O
pattern O
of O
the O
re O
- O
enlarged O
( O
Fig.1A O
) O
was O
very O
similar O
to O
the O
initial O
pretreatment O
CNV O
, O
suggesting O
that O
the O
recurrence O
may O
be O
reopening O
of O
original O
channels O
rather O
than O
growth O
of O
new O
vessels O
. O

 O
Comparing O
the O
CNV O
network O
prior O
to O
the O
3rd O
injection O
to O
the O
baseline O
, O
it O
is O
notable O
that O
there O
were O
fewer O
smaller O
channels O
, O
while O
the O
larger O
caliber O
channels O
remained O
. O

 O
Quantitative O
measurements O
from O
( O
Fig.2A O
) O
showed O
reduction O
in O
and O
over B
the I
first I
2 I
weeks I
with O
subsequent O
return O
. O

 O
Retinal O
thickness O
( O
Fig.2B O
) O
showed O
the O
fluid O
resorption O
over O
the O
first O
4 O
weeks O
in O
the O
first O
treatment O
cycle O
continuing O
at O
least O
2 O
weeks O
into O
the O
second O
treatment O
cycle O
, O
at O
which O
time O
no O
fluid O
remained O
( O
Fig.1B O
) O
. O

 O
But O
after O
the O
2nd O
injection O
. O

 O
( O
Fig.2B O
) O
over O
the O
3 O
treatment O
cycles O
. O

Our O
non O
- O
smoking O
patient O
with O
repeated O
in O
with O
4 B
days I
of O
concomitant O
right O
thoracic O
. O

 O
During O
, O
this O
patient O
suffered O
from O
a O
with O
and O
a O
strong O
. O

 O
The O
strong O
dry O

 O
The O
patient O
did O
not O
report O
any O
. O

 O
The O
initial O
of O
the O
showed O
a O
solid O
paravertebral O
right O
in O
the O
lower O
thorax O
without O
any O
signs O
of O
( O
Figure O
1 O
) O
. O

 O
The O
( O
Figure O
​2 O
) O
with O
non O
- O
bleeding O
revealed O
a O
of O
the O
which O
and O
provided O
evidence O
of O
a O
or O
Abrikossoff O
[ O
1 O
] O
. O

 O
The O
which O
followed O
was O
for O
. O

 O
The O
patient O
was O
and O
surgical O
intervention O
was O
planned O
. O

 O
a O
spontaneous O
developed O
. O

 O
The O
patient O
needed O
to O
be O
and O
the O
hemothorax O
was O
. O

 O
No O
malignant O
cells O
were O
detected O
in O
the O
of O
the O
. O

 O
After O
an O
uneventful O
course O
and O
decreasing O
of O
the O
, O
the O
tumor O
was O
by O
performing O
a O

 O
The O
final O
confirmed O
a O
peribronchial O
and O
infiltrating O
S100 O
positive O
supporting O
the O
Schwann O
cell O
origin O
theory O
with O
very O
low O
of O
and O
a O
of O
( O
Figure O
​3 O
) O
. O

A O
at O
the O
, O
12 O
h O
after O
of O
a O
with O
tanning O
spray O
into O
his O
. O

 O
A O
plain O
abdominal O
( O
Figure O
1 O
) O
showed O
the O
container O
in O
the O
rectosigmoid O
region O
. O

 O
There O
were O
no O
signs O
of O
. O

 O
A O
flexible O
was O
performed O
under O
. O

 O
The O
was O
located O
just O
. O

 O
The O
could O
not O
be O
by O
. O

 O
An O
attempt O
to O
the O
object O
with O
, O
such O
as O
, O
was O
. O

 O
The O
could O
be O
passed O
alongside O
the O
to O
its O
proximal O
end O
. O

 O
A O
guide O
wire O
was O
left O
behind O
with O
the O
sigmoidoscope O
removed O
. O

 O
Subsequently O
, O
a O
40 O
mm O
( O
Rigiflex O
® O
, O
Boston O
Scientific O
) O
, O
normally O
used O
in O
achalasia O
patients O
, O
was O
inserted O
over O
the O
guide O
wire O
and O
inflated O
just O
above O
the O
( O
Figure O
2 O
) O
. O

 O
For O
safety O
purposes O
, O
the O
was O
reintroduced O
alongside O
the O
catheter O
of O
the O
to O
allow O
endoscopic O
visual O
control O
of O
the O
distal O
end O
of O
the O
in O
the O
. O

 O
Gentle O
traction O
was O
exerted O
on O
the O
catheter O
, O
and O
the O
was O
successfully O
under O
( O
Figure O
​3 O
) O
. O

The O
proband O
is O
a O
, O
first O
child O
of O
healthy O
unrelated O
parents O
. O

 O
Her O
. O

 O
She O
was O
. O

 O
The O
perinatal O
period O
was O
uneventful O
and O
her O
was O
referred O
to O
as O
, O
but O
after O
, O
became O
evident O
. O

 O
She O
started O
walking O
autonomously O
at O
22 O
  O
months O
, O
with O
poor O
and O
frequent O
. O

 O
At O
, O
she O
developed O
a O
and O
a O
brain O
disclosed O
supratentorial O
. O

 O
During O
her O
childhood O
, O
the O
remained O
. O

 O
At O
, O
her O
, O
and O
limb O
and O
ensued O
. O

 O
The O
showed O
, O
, O
ataxic O
and O
in O
the O
with O
. O

 O
She O
was O
able O
to O
walk O
alone O
only O
for O
a O
few O
steps O
with O
an O
ataxic O
. O

 O
Mild O
was O
documented O
( O
75 O
, O
) O
. O

 O
of O
a O
muscle O
showed O
of O
. O

 O
The O
was O
. O

 O
At O
her O
last O
examination O
, O
at O
, O
she O
was O
able O
to O
only O
with O
ankle O
- O
foot O
and O
had O
developed O
a O
marked O
dorsal O
- O
lumbar O
. O

 O
Other O
were O
. O

 O
confirmed O
worsening O
of O
her O
mixed O
axonal O
. O

 O
Brain O
and O
spinal O
cord O
showed O
mild O
extension O
of O
and O
extensive O
in O
the O
; O
the O
cerebellum O
and O
brainstem O
were O
spared O
but O
the O
spinal O
cord O
was O
thin O
with O
no O
obvious O
focal O
( O
figure O
1A O
) O
. O

 O
was O
( O
n.v O
. O
< O
2.1 O
) O
. O

A O
was O
to O
our O
hospital O
for O
perioperative O
cardiac O
evaluation O
of O
abdominal O
aortic O
. O

 O
The O
patient O
had O
undergone O
coronary O
artery O
bypass O
grafting O
( O
CABG O
) O
for O
severe O
stenosis O
of O
the O
left O
main O
coronary O
artery O
( O
LMCA O
) O
, O
which O
consisted O
of O
the O
( O
) O
to O
the O
( O
) O
and O
( O
) O
to O
the O
( O
) O
. O

 O
Due O
to O
continual O
growth O
of O
the O
abdominal O
aortic O
aneurysm O
over O
the O
years O
, O
surgery O
was O
indicated O
. O

 O
Left O
coronary O
angiogram O
showed O
90 O
% O
stenosis O
of O
the O
LMCA O
and O
total O
occlusion O
of O
both O
grafts O
. O

 O
PCI O
was O
performed O
for O
LMCA O
stenosis O
( O
Fig.1 O
) O
. O

 O
A O
7 O
- O
Fr O
sheath O
was O
inserted O
into O
the O
right O
femoral O
artery O
, O
and O
a O
CLS4 O
guiding O
catheter O
( O
Boston O
Scientific O
, O
Natick O
, O
MA O
, O
USA O
) O
was O
engaged O
into O
the O
left O
coronary O
artery O
( O
LCA O
) O
ostium O
. O

 O
A O
guidewire O
( O
SION O
Blue O
, O
Asahi O
Intecc O
, O
Aichi O
, O
Japan O
) O
was O
inserted O
into O
the O
distal O
LAD O
, O
and O
another O
guidewire O
( O
Hi O
- O
Torque O
Pilot O
50 O
, O
Abbott O
Vascular O
, O
Santa O
Clara O
, O
California O
, O
USA O
) O
was O
inserted O
into O
the O
distal O
LCX O
. O

 O
Intravascular O
ultrasound O
( O
IVUS O
) O
( O
Intra O
- O
focus O
WR O
, O
Terumo O
Corp O
, O
Tokyo O
, O
Japan O
) O
demonstrated O
heavy O
circumferential O
calcification O
in O
the O
LMCA O
lesion O
. O

 O
After O
a O
4.0 O
  O
× O
  O
15 O
- O
mm O
Quantum O
Maverick O
balloon O
catheter O
( O
Boston O
Scientific O
) O
was O
inflated O
in O
the O
lesion O
, O
LCA O
angiogram O
revealed O
a O
large O
dissection O
( O
Fig.2 O
) O
. O

 O
A O
4.0 O
  O
× O
  O
28 O
- O
mm O
Multi O
- O
Link O
Vision O
stent O
( O
Abbott O
Vascular O
) O
was O
immediately O
deployed O
. O

 O
Angiographic O
image O
of O
the O
residual O
dissection O
disappeared O
and O
the O
stent O
was O
dilated O
by O
a O
5.0 O
  O
× O
  O
15 O
- O
mm O
Quantum O
Maverick O
balloon O
catheter O
. O

 O
The O
absence O
of O
residual O
dissection O
was O
confirmed O
by O
angiography O
after O
stent O
implantation O
. O

 O
Next O
, O
LMCA O
- O
LAD O
and O
LMCA O
- O
LCX O
kissing O
balloon O
angioplasty O
was O
initiated O
using O
a O
4.0 O
  O
× O
  O
28 O
- O
mm O
stent O
delivery O
balloon O
in O
the O
LAD O
and O
a O
3.0 O
mm O
  O
× O
  O
15 O
- O
mm O
Ikazuchi O
balloon O
( O
Kaneka O
Medics O
, O
Tokyo O
, O
Japan O
) O
in O
the O
LCX O
. O

 O
The O
final O
angiographic O
imaging O
showed O
optimal O
results O
, O
and O
IVUS O
imaging O
of O
the O
lesion O
showed O
completely O
sealing O
by O
the O
stent O
( O
Fig.3 O
) O
. O

 O
A O
large O
hematoma O
at O
the O
femoral O
puncture O
site O
and O
local O
bleeding O
was O
observed O
after O
removal O
of O
the O
femoral O
sheath O
and O
manual O
compression O
was O
applied O
for O
haemostasis O
. O

 O
The O
hematoma O
did O
not O
appear O
to O
have O
spread O
the O
next O
day O
and O
the O
patient O
was O
discharged O
from O
the O
hospital O
on O
the O
fifth O
day O
after O
PCI O
. O

 O
Unexpectedly O
, O
the O
patient O
was O
admitted O
to O
our O
emergency O
room O
with O
new O
- O
onset O
chest O
pain O
and O
dyspnoea O
the O
next O
day O
after O
the O
discharge O
. O

 O
His O
vital O
signs O
indicated O
cardiogenic O
shock O
. O

 O
Electrocardiogram O
showed O
ST O
elevation O
in O
leads O
V1 O
- O
V3 O
. O

 O
Although O
echocardiography O
could O
not O
detect O
left O
ventricular O
asynergy O
, O
a O
large O
mass O
on O
the O
outflow O
tract O
of O
right O
ventricular O
chamber O
was O
observed O
( O
Fig.4 O
) O
. O

 O
Contrast O
- O
enhanced O
computed O
tomography O
showed O
a O
40 O
- O
mm O
hematoma O
compressing O
the O
main O
pulmonary O
artery O
trunk O
and O
the O
right O
ventricle O
( O
Fig.5 O
) O
. O

 O
During O
examination O
, O
the O
patient O
suffered O
sudden O
cardiopulmonary O
arrest O
. O

 O
He O
received O
immediate O
cardiopulmonary O
resuscitation O
and O
returned O
to O
spontaneous O
circulation O
after O
the O
insertion O
of O
a O
percutaneous O
cardiopulmonary O
support O
device O
. O

 O
The O
patient O
underwent O
emergent O
surgery O
for O
the O
removal O
of O
the O
hematoma O
after O
informed O
consent O
was O
obtained O
from O
the O
patient O
's O
family O
. O

 O
During O
surgery O
, O
large O
, O
dark O
red O
clots O
between O
the O
pulmonary O
artery O
trunk O
and O
aorta O
were O
observed O
. O

 O
The O
suspected O
origin O
of O
the O
epicardial O
hematoma O
was O
blood O
oozing O
from O
the O
LMCA O
stent O
site O
. O

 O
Despite O
successful O
surgical O
repair O
, O
the O
patient O
from O
aortic O
rupture O
induced O
by O
. O

